Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 3, 2013, Pages 460-466

  Hilliard, P ^a   Zourikian, N ^b   Blanchette, V ^a   Chan, A ^c   Elliott, B ^d   Israels, S J ^e   Nilson, J ^f   Poon, M C ^g   Laferriere, N ^h   Van Neste, C ⁱ   Jarock, C ^j   Wu, J ^k   Mclimont, M ^a   Feldman, B ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^e UNIVERSITY OF MANITOBA   (Canada)

^f ROYAL UNIVERSITY HOSPITAL   (Canada)

^g UNIVERSITY OF CALGARY   (Canada)

^h THUNDER BAY REGIONAL HEALTH SCIENCES CENTRE   (Canada)

ⁱ LAVAL UNIVERSITY   (Canada)

^j IWK HEALTH CENTRE   (Canada)

^k UNIVERSITY OF BRITISH COLUMBIA   (Canada)

more..

Author keywords

Hemarthrosis; Hemophilia; Joint; Prophylaxis

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8;

ARTICLE; BLEEDING; CANADA; CHILD; CHILDHOOD HEALTH ASSESSMENT QUESTIONNAIRE; DISEASE SEVERITY; DRUG DOSE ESCALATION; FOLLOW UP; HEMOPHILIA A; HUMAN; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; MODIFIED COLORADO PHYSICAL EVALUATION SCALE; MUSCLE ATROPHY; MUSCULOSKELETAL SYSTEM; PHYSICAL EXAMINATION; PRESCHOOL CHILD; PRIORITY JOURNAL; QUESTIONNAIRE; RANGE OF MOTION; RATING SCALE;

BIOMECHANICS; CANADA; CHILD; CHILD, PRESCHOOL; COAGULANTS; DISABILITY EVALUATION; DRUG ADMINISTRATION SCHEDULE; FACTOR VIII; HEMARTHROSIS; HEMOPHILIA A; HUMANS; INFANT; JOINTS; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; MALE; MUSCULAR ATROPHY; PHYSICAL EXAMINATION; QUESTIONNAIRES; RANGE OF MOTION, ARTICULAR; RECOMBINANT PROTEINS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84874967483     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12113     Document Type: Article

References (20)

1. van den Berg HM, Dunn A, Fischer K, Blanchette VS. Prevention and treatment of musculoskeletal disease in the haemophilia population: role of prophylaxis and synovectomy. Haemophilia 2006; 12(Suppl 3): 159-68.
2. Panicker J, Warrier I, Thomas R, Lusher JM. The overall effectiveness of prophylaxis in severe haemophilia. Haemophilia 2003; 9: 272-8.
3. Roosendaal G, Lafeber FP. Pathogenesis of haemophilic arthropathy. Haemophilia 2006; 12(Suppl 3): 117-21.
4. Manco-Johnson MJ. Update on treatment regimens: prophylaxis versus on-demand therapy. Semin Hematol 2003; 40: 3-9.
5. Gilbert MS. Prophylaxis: musculoskeletal evaluation. Semin Hematol 1993; 30: 3-6.
6. Manco-Johnson MJ, Nuss R, Funk S, Murphy J. Joint evaluation instruments for children and adults with haemophilia. Haemophilia 2000; 6: 649-57.
7. Hilliard P, Funk S, Zourikian N, Bergstrom BM, Bradley CS, McLimont M, Manco-Johnson M, Petrini P, van den Berg M, Feldman BM. Hemophilia joint health score reliability study. Haemophilia 2006; 12: 518-25.
8. Hacker MR, Funk SM, Manco-Johnson MJ. The Colorado Haemophilia Paediatric Joint Physical Examination Scale: normal values and interrater reliability. Haemophilia 2007; 13: 71-8.
9. Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Manco-Johnson ML, Funk S, Jacobson L, Valentino LA, Hoots WK, Buchanan GR, DiMichele D, Recht M, Brown D, Leissinger C, Bleak S, Cohen A, Mathew P, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
10. Feldman BM, Funk SM, Bergstrom BM, Zourikian N, Hilliard P, van der Net J, Engelbert R, Petrini P, van den Berg HM, Manco-Johnson MJ, Rivard GE, Abad A, Blanchette VS. Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: validity of the hemophilia joint health score. Arthritis Care Res (Hoboken) 2011; 63: 223-30.
11. Löfqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients-a long-term follow-up. J Intern Med 1997; 241: 395-400.
12. Gringeri A. Prospective controlled studies on prophylaxis: an Italian approach. Haemophilia 2003; 9: 38-43.
13. Santagostino E, Mancuso ME. Venous access in haemophilic children: choice and management. Haemophilia 2010; 16(Suppl 1): 20-4.
14. Santagostino E, Mancuso ME. Barriers to primary prophylaxis in haemophilic children: the issue of the venous access. Blood Transfus 2008; 6(Suppl 2): s12-6.
15. Fischer K, van der Bom JG, Molho P, Negrier C, Mauser-Bunschoten EP, Roosendaal G, De Kleijn P, Grobbee DE, van den Berg HM. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia 2002; 8: 745-52.
16. Feldman BM, Pai M, Rivard GE, Israels S, Poon MC, Demers C, Robinson S, Luke KH, Wu JKM, Gill K, Lillicrap D, Babyn P, McLimont M, Blanchette VS, The Association of Hemophilia Clinic Directors of Canada Prophylaxis Study Group. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006; 4: 1228-36.
17. Hang MX, Blanchette VS, Pullenayegum E, McLimont M, Feldman BM. Age at first joint bleed and bleeding severity in boys with severe hemophilia A: Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2011; 9: 1067-9.
18. Dempster H, Porepa M, Young N, Feldman BM. The clinical meaning of functional outcome scores in children with juvenile arthritis. Arthritis Rheum 2001; 44: 1768-74.
19. Olivieri M, Kurnik K, Pfluger T, Bidlingmaier C. Identification and long-term observation of early joint damage by magnetic resonance imaging in clinically asymptomatic joints in patients with haemophilia A or B despite prophylaxis. Haemophilia 2012; 18: 369-74.
20. De Valentine SJ. Foot and Ankle Disorders in Children New York: Churchill Livingstone, 1992.